12th International Conference on Myasthenia Gravis and Related Disorders

第十二届重症肌无力及相关疾病国际会议

基本信息

批准号：
8256499
负责人：
Matthew Nicholas Meriggioli
金额：
$ 2万
依托单位：
NEW YORK ACADEMY OF SCIENCES
依托单位国家：
美国
项目类别：
财政年份：
2011
资助国家：
美国
起止时间：
2011-09-30 至 2012-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8256499
关键词：
Academia Academy Americas Antibodies Area Autoimmune Diseases Autoimmune Process Autoimmunity Basic Science Chicago Classification Clinic Clinical Clinical Research Clinical Trials Collaborations Communities Congresses Country Critiques Development Diagnosis Disease Disease Management Doctor of Philosophy Drug Delivery Systems Evaluation Failure Fellowship Foundations Future Goals Government Illinois Immunology Individual Industry International Laboratory Research Lambert-Eaton Myasthenic Syndrome Life Location Measurement Medical Medical center Medicine Modeling Multimedia Muscle Weakness Myasthenia Gravis Neurology Neuromuscular Diseases Neuromuscular Junction Neurosciences New York Nicotinic Receptors Nonprofit Organizations Oral Outcome Participant Pathogenesis Patients Physicians Physiology Postdoctoral Fellow Printing Proteins Publishing Research Research Personnel Science Seasons Senior Scientist Series Structure Students Study Section Synapses Synaptic Transmission Syndrome Texas Therapeutic Thymectomy Time Translational Research Travel Underrepresented Minority Universities Update Validation Work Writing abstracting animal model development base bench to bedside college disability experience graduate student improved meetings multidisciplinary neuromuscular neuromuscular transmission new therapeutic target novel posters programs receptor structure function symposium therapeutic target web site

项目摘要

DESCRIPTION: Myasthenia gravis (MG) is a relatively rare, acquired autoimmune syndrome resulting from pathogenic auto- antibodies that cause failure of neuromuscular synaptic transmission. The disease often produces severe muscle weakness leading to significant disability and can be life-threatening. Despite notable improvements in diagnosis and treatment of MG, significant hurdles remain that will require synthesis of research from basic, translational and clinical domains to overcome. The New York Academy of Sciences and the Myasthenia Gravis Foundation of America will convene the 3-day 12th International Conference on Myasthenia Gravis and Related Disorders on May 21-23, 2012 at the New York Academy of Sciences Conference Center in New York, NY. The forthcoming conference represents a long-standing collaboration between these non-profit organizations. The co-PIs on this project are Matthew N. Meriggioli (PI), MD, University of Illinois College of Medicine at Chicago and Gil I. Wolfe (PI), MD, University of Texas Southwestern Medical Center Dallas. In the four years since the 11th International Conference, a number of important breakthroughs have led to the identification of novel potential therapeutic targets for MG and related disorders, advancements in the clinical classification of MG subtypes, and the initiation of a number of new clinical trial for improved MG treatment options, making this an ideal time to reconvene this community to review these findings and discuss the future of research in this area. Ten plenary sessions will span the full spectrum of research from bench to bedside, including structure and function of the neuromuscular junction, advances in immunology, recent clinical developments related to MG, outcome measurements, clinical trial development, animal models of neuromuscular disease, MG treatment updates, congenital and Lambert-Eaton myasthenic syndromes, and thymectomy and the MGTX trial. Participants will be encouraged to interact during panel discussions and networking receptions, and junior investigators will be especially encouraged to participate through reduced registration rates, travel fellowships, and inclusion of 2 poster sessions and student oral presentations. The goals of this program are to: 1) provide a forum for basic, translational, and clinical researchers from academia and industry to present and discuss the most up-to-date findings in MG research; 2) explore and encourage multidisciplinary and multi-sector collaborations to enhance investigative approaches into MG and related autoimmune and neuromuscular disorders; 3) review current MG therapeutic options, ongoing clinical trials, and challenges and limitations faced in the clinic; 4) attract and maintain young and underrepresented minority investigators to the field and provide a venue for junior and senior scientists to establish new relationships and collaborations; and 5) reach a global scientific community by disseminating conference proceedings via our website and the Annals of the New York Academy of Sciences. PUBLIC HEALTH RELEVANCE: The International Conference on Myasthenia Gravis and Related Disorders has been held approximately every 5 years since 1954 to promote the exchange of scientific and medical information among international, multidisciplinary clinical, translational, and basic researchers studying neuromuscular transmission and autoimmune disorders. The broad objectives of the 12th installment of this series are to present and discuss up-to-date laboratory and clinical research related to myasthenia gravis and related disorders to stimulate improved diagnosis, therapeutics, and management of these diseases. The cross-disciplinary discussions among participants during the conference, the online and print dissemination of the conference proceedings, and the new research collaborations generated at the meeting will stimulate the identification and validation of novel drug targets, development of improved clinical trials, and establishment of an agenda for future research on myasthenia gravis and related disorders. Disclaimer: Please note that the following critiques were prepared by the reviewers prior to the Study Section meeting and are provided in an essentially unedited form. While there is opportunity for the reviewers to update or revise their written evaluation, based upon the group's discussion, there is no guarantee that individual critiques have been updated subsequent to the discussion at the meeting. Therefore, the critiques may not fully reflect the final opinions of th individual reviewers at the close of group discussion or the final majority opinion of the group. Thus the Resume and Summary of Discussion is the final word on what the reviewers actually considered critical at the meeting.

描述：肌无力重症（MG）是一种相对罕见的，获得的自身免疫性综合征，这是由于致病性自动抗体导致神经肌肉突触传播失败的原因。该疾病通常会导致严重的肌肉无力导致严重的残疾，并可能威胁生命。尽管在诊断和治疗MG方面有了显着改善，但仍需要从基本，转化和临床领域综合研究的重大障碍才能克服。纽约科学院和美国肌无力的肌无力将于2012年5月21日至23日在纽约纽约纽约纽约纽约科学院会议中心举行的为期3天的第12届国际肌无力及相关疾病。即将举行的会议代表了这些非营利组织之间的长期合作。该项目的共同提示是芝加哥伊利诺伊大学医学院医学博士Matthew N. Meriggioli（PI）和德克萨斯大学西南医学中心达拉斯大学医学博士Gil I. Wolfe（PI）。自第11届国际会议以来的四年中，许多重要的突破导致了对MG和相关疾病的新型潜在治疗靶标，MG亚型临床分类的进步以及许多新的临床试验的启动，以改善MG治疗方案，以改善MG治疗方案，从而使该社区重新讨论这些领域的理想时间，以研究这些领域和研究这些领域。 Ten plenary sessions will span the full spectrum of research from bench to bedside, including structure and function of the neuromuscular junction, advances in immunology, recent clinical developments related to MG, outcome measurements, clinical trial development, animal models of neuromuscular disease, MG treatment updates, congenital and Lambert-Eaton myasthenic syndromes, and thymectomy and the MGTX trial.将鼓励参与者在小组讨论和网络招待会上进行互动，并特别鼓励参与者通过降低的注册率，旅行奖学金以及包括2次海报会议和学生口头演讲来参加。该计划的目标是：1）为来自学术界和行业的基本，转化和临床研究人员提供论坛，以介绍和讨论MG研究中最新的发现； 2）探索和鼓励多学科和多部门的合作，以增强对MG和相关自身免疫性和神经肌肉疾病的调查方法； 3）审查当前的MG治疗选择，正在进行的临床试验以及诊所面临的挑战和局限性； 4）吸引并维持年轻和代表性不足的少数群体调查员进入该领域，并为初级和高级科学家建立新的关系和合作提供了一个场所； 5）通过通过我们的网站和纽约科学院的纪事来传播会议会议记录，到达全球科学界。公共卫生相关性：自1954年以来，大约每5年举行了一次每5年举行一次关于肌无力的肌无力和相关疾病的国际会议，以促进研究神经肌肉传播和自身免疫性疾病的国际，多学科临床，翻译，转化和基础研究人员之间的科学和医学信息。本系列第十二期的广泛目标是介绍和讨论与重症肌无力和相关疾病有关的最新实验室和临床研究，以刺激这些疾病的诊断，治疗剂和治疗。会议期间，参与者之间的跨学科讨论，在线和印刷会议会议上的传播以及会议上产生的新研究合作将刺激新型药物目标的识别和验证，改进的临床试验的发展以及建立了对疗程疗程和相关疗法的未来研究的议程。免责声明：请注意，以下批评是由审稿人在研究部分会议之前准备的，并以本质上未经编辑的形式提供。尽管审稿人有机会根据小组的讨论来更新或修改其书面评估，但不能保证在会议上讨论后对个人批评进行了更新。因此，批评可能无法完全反映在小组讨论结束时，个人审稿人的最终意见或小组的最终多数意见。因此，讨论的简历和摘要是审稿人在会议上实际认为至关重要的最终词。